LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

Home・Aandelen Lijst・Kymera Therapeutics Inc

Kymera Therapeutics Inc

Gesloten

SectorGezondheidszorg

64.61 1.3

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

64.49

Max

68.3

Belangrijke statistieken
By Trading Economics
Inkomsten	-5.6M -82M
Verkoop	-8.7M 2.8M
EPS	-0.94
Winstmarge	-2,973.046
Werknemers	225
EBITDA	-1.3M -86M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+12.75% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	138M 4.4B
Vorige openingsprijs	63.31
Vorige sluitingsprijs	64.61

Nieuwssentiment

By Acuity

50%

160 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

28.34 / 33.56 Steun & Weerstand

Kymera Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 nov 2025, 17:45 UTC

Winsten

Belangrijke Marktbewegers

Figure Technology Shares Rise After Higher 3Q Earnings, Revenue

14 nov 2025, 17:31 UTC

Winsten

Belangrijke Marktbewegers

American Bitcoin Advances on 3Q Profit, Eric Trump's Crypto Confidence

15 nov 2025, 18:03 UTC

Winsten

Kugler Resignation From Fed Board Followed Disclosures of Improper Stock Trades -- UPDATED -- WSJ

15 nov 2025, 15:43 UTC

Winsten

Kugler Resignation From Fed Board Followed Disclosures of Improper Stock Trades -- WSJ

15 nov 2025, 12:00 UTC

Winsten

Meta Opens Pop-Up Stores to Build Buzz for Its AI Glasses -- WSJ

15 nov 2025, 09:20 UTC

Marktinformatie

Winsten

Tech, Media & Telecom Roundup: Market Talk

15 nov 2025, 09:20 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

15 nov 2025, 00:08 UTC

Acquisities, Fusies, Overnames

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 3rd Update

14 nov 2025, 23:56 UTC

Acquisities, Fusies, Overnames

Berkshire Hathaway Bought Alphabet Shares Worth $4.3 Billion in the Third Quarter. Here's What It Sold. -- Barrons.com

14 nov 2025, 23:02 UTC

Marktinformatie

Chinese Battery Makers Benefit From U.S. Rising Demand -- Market Talk

14 nov 2025, 22:35 UTC

Winsten

Acquisities, Fusies, Overnames

The Score: Tyson, Robinhood, Walmart, Paramount Skydance and More Stocks That Defined the Week -- WSJ

14 nov 2025, 22:32 UTC

Acquisities, Fusies, Overnames

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 2nd Update

14 nov 2025, 22:29 UTC

Winsten

Starbucks Scores on Holiday Sales. It's a Good Sign for the Turnaround. -- Barrons.com

14 nov 2025, 22:00 UTC

Acquisities, Fusies, Overnames

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- Update

14 nov 2025, 21:50 UTC

Marktinformatie

Winsten

Tech, Media & Telecom Roundup: Market Talk

14 nov 2025, 21:18 UTC

Acquisities, Fusies, Overnames

Berkshire Buys Shares of Alphabet and Pares Apple Stake -- WSJ

14 nov 2025, 20:27 UTC

Marktinformatie

Oil Futures Rise After Ukraine Strikes Russian Port -- Market Talk

14 nov 2025, 20:23 UTC

Marktinformatie

U.S. Natural Gas Futures Post Weekly Gain -- Market Talk

14 nov 2025, 20:17 UTC

Acquisities, Fusies, Overnames

Several State Attorneys General Oppose Railroad Merger -- WSJ

14 nov 2025, 19:29 UTC

Marktinformatie

Winsten

Applied Materials' F4Q Results Seen as 'Uninspiring' -- Market Talk

14 nov 2025, 18:44 UTC

Marktinformatie

Winsten

Disney's Growth Now Hinges More on ESPN -- Market Talk

14 nov 2025, 18:27 UTC

Marktinformatie

Global Equities Roundup: Market Talk

14 nov 2025, 18:27 UTC

Marktinformatie

Morgan Stanley Sees 'Worthy Successor' in Walmart CEO Furner -- Market Talk

14 nov 2025, 18:20 UTC

Marktinformatie

U.S. Oil Rig Count Rises by 3 to 417 -- Market Talk

14 nov 2025, 17:20 UTC

Marktinformatie

Winsten

Auto & Transport Roundup: Market Talk

14 nov 2025, 17:20 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Health Care Roundup: Market Talk

14 nov 2025, 17:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

14 nov 2025, 16:51 UTC

Marktinformatie

Starbucks Gets Holiday Sales Lift -- Market Talk

14 nov 2025, 16:48 UTC

Marktinformatie

Gold Slides Amid Selloff, Lower December Fed Rate-Cut Expectations -- Market Talk

14 nov 2025, 16:38 UTC

Marktinformatie

Unica Reports Higher Brazilian Sugar and Ethanol Production -- Market Talk

Peer Vergelijking

Prijswijziging

Kymera Therapeutics Inc Prognose

Koersdoel

By TipRanks

12.75% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 73.22 USD 12.75%

Hoogste 90 USD

Laagste 53 USD

Gebaseerd op 20 Wall Street-analisten die 12-maands prijsdoelen bieden voor Kymera Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

20 ratings

Buy

Hold

Sell

Gebaseerd op 20 analisten die aandelenratings hebben gegeven aan Kymera Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

28.34 / 33.56Steun & Weerstand

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

Sentiment

By Acuity

160 / 374 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Kymera Therapeutics Inc

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.